MedElevator
Войти в исследования International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
In vitro characterization of delafloxacin activity against intracellular Legionella: Exploring new treatment options for Legionnaires' disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cortès-Tarragó Roger, Arqué Elisenda, Vinyeta Lluc, Basart Altieri Maria, Elizondo Sarahi Marieliza, Sopena Nieves, Reynaga Esteban, Díez de Los Ríos Javier, Quero Sara, Párraga-Niño Noemí, Pedro-Botet Luisa
Аннотация
OBJECTIVES: Delafloxacin is a fourth-generation fluoroquinolone that is currently approved in Europe and the United States for bacterial infections of the skin and skin structures and for community-acquired pneumonia, including cases where it is caused by atypical pathogens. It has demonstrated superior efficacy against a broad spectrum of bacteria and fewer adverse effects compared with other quinolones, such as levofloxacin, a current first-line treatment against Legionnaires' disease. This study aimed to characterize for the first time the intracellular activity of delafloxacin compared with levofloxacin against various serogroups of Legionella pneumophila and species of Legionella in terms of culturability and viability.
METHODS: The infectious capacity of 10 Legionella strains was evaluated individually to ensure a percentage of viable infected macrophage post-infection. Then, the extracellular concentration inhibiting intracellular multiplication (MIEC90) of the antibiotic was determined by gradient antibiotic incubations in the in vitro infection model through culturability assays. Finally, the viability of intracellular Legionella was studied by quantitative polymerase chain reaction after antibiotic treatment at MIEC90 value.
RESULTS: Delafloxacin decreased the culturability of Legionella from five to 10 times more than levofloxacin. The MIEC90 obtained was 0.025 mg/l for levofloxacin and 0.005 mg/l for delafloxacin for all strains tested, except L. longbeachae; the same concentration for both antibiotics was required. The bactericidal effect of both antibiotics was confirmed by viability quantitative polymerase chain reaction.
CONCLUSIONS: Based on the results obtained, the higher intracellular activity of delafloxacin compared with levofloxacin and its better safety profile should be confirmed in phase IV clinical real-life cases of Legionnaires' disease.
METHODS: The infectious capacity of 10 Legionella strains was evaluated individually to ensure a percentage of viable infected macrophage post-infection. Then, the extracellular concentration inhibiting intracellular multiplication (MIEC90) of the antibiotic was determined by gradient antibiotic incubations in the in vitro infection model through culturability assays. Finally, the viability of intracellular Legionella was studied by quantitative polymerase chain reaction after antibiotic treatment at MIEC90 value.
RESULTS: Delafloxacin decreased the culturability of Legionella from five to 10 times more than levofloxacin. The MIEC90 obtained was 0.025 mg/l for levofloxacin and 0.005 mg/l for delafloxacin for all strains tested, except L. longbeachae; the same concentration for both antibiotics was required. The bactericidal effect of both antibiotics was confirmed by viability quantitative polymerase chain reaction.
CONCLUSIONS: Based on the results obtained, the higher intracellular activity of delafloxacin compared with levofloxacin and its better safety profile should be confirmed in phase IV clinical real-life cases of Legionnaires' disease.